Workflow
华北制药(600812) - 2024 Q2 - 季度业绩预告
NCPCNCPC(SH:600812)2024-07-10 11:11

Financial Performance - The company expects a net profit attributable to shareholders of approximately 70 million yuan for the first half of 2024, an increase of about 43.45 million yuan or 164% compared to the same period last year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be around 52 million yuan, representing an increase of approximately 50.94 million yuan or 4,810% year-on-year[12]. - The previous year's net profit attributable to shareholders was approximately 26.55 million yuan, with a net profit after deducting non-recurring gains and losses of about 1.06 million yuan[14]. - The performance forecast indicates that the company has achieved profitability[12]. Operational Measures - The company has implemented measures such as adjusting product structure, enhancing procurement management, and controlling costs to improve profitability[1]. - The company is focused on enhancing its operational efficiency through lean management practices[1]. Forecast and Risks - The preliminary financial data is subject to final confirmation in the official 2024 semi-annual report, and investors are advised to be aware of investment risks[3]. - The company has not identified any significant uncertainties that could affect the accuracy of the performance forecast[2]. - The earnings forecast period is from January 1, 2024, to June 30, 2024[13]. - The company’s board of directors guarantees the truthfulness, accuracy, and completeness of the announcement content[11].